Maverix Biomics And Elsevier Sign Cooperation Agreement

- Maverix Analytic Platform integrates with Elsevier Pathway Studio for seamless NGS analysis workflow to assist critical decision making -

Feb 16, 2015, 12:30 ET from Maverix Biomics

SAN FRANCISCO, Feb. 16, 2015 /PRNewswire/ -- Maverix Biomics, Inc. today announced at the 23rd International Molecular Medicine Tri-Conference (Tricon) in San Francisco, CA that the company has signed a strategic cooperation agreement with Elsevier, a world-leading provider of scientific, technical and medical information products and services, to streamline the interpretation of raw next-generation sequencing (NGS) data to reveal new insights and to assist with critical decision making. The Maverix Analytic Platform will complement Pathway Studio's sample-to-insight workflow and incorporation of biological data from Elsevier's biology journals by providing easy, push-button data analysis, which is now integrated with Elsevier's Pathway Studio research solution for biologists. Financial terms were not disclosed.

The combination of the Maverix Analytic Platform and Elsevier's Pathway Studio is an integrated solution that starts with raw NGS data and quickly produces genome alignment, quality metrics, variant and expression analysis, and the ability to analyze and visualize disease mechanisms derived from published scientific data.

Today at Tricon, Maverix Biomics' Chief Scientific Officer Todd Lowe is chairing a keynote session entitled "Advances in Genome and Transcriptome Analysis," which will address advances in areas such as single cell analysis and CRISPR genome editing, as well as the use of DNA-seq variant analysis and RNA-seq expression analysis in fields such as clinical research and diagnostics as well as the workflow challenges in these settings.

"This collaboration gives more value to our customers – not only can they use the two great tools our companies produce, but they can now save time by seamlessly using them together. This reduces their workload, reduces complexity and increases accuracy of their analysis," said Jaqui Hodgkinson, VP Product Development of Elsevier Life Sciences Solutions.

"We are pleased to be able to offer the Maverix Analytic Platform directly integrated with the Elsevier's Pathway Studio solution for researchers," said Dave Mandelkern, Maverix president and co-founder. "The combined offering will help researchers unravel hidden biology in experimental data or literature-based evidence, which will be especially useful in building and visualizing disease models."

About Pathway Studio®

Pathway Studio is integrated data mining and visualization software with a high-quality, comprehensive knowledgebase produced by applying Elsevier's proprietary text-mining technology to a large corpus of biological literature. Pathway Studio allows organizations and researchers to rapidly connect relevant biological facts and relationships, integrate and interpret experimental data, and visualize the results. Pathway Studio is used for defining and testing in silico-based hypotheses across a wide range of disciplines including mechanistic modeling of disease, drug action and toxicity, target discovery and validation, biomarker discovery, cellular and network pathway building, protein-protein interactions and many more.

Pathway Studio is offered in configurations that scale to support individual researchers and global corporations with access to custom and domain-specific knowledgebases. For more information, visit the Pathway Studio website: http://www.elsevier.com/online-tools/pathway-studio

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 33,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About the Maverix Analytic Platform

The Maverix Analytic Platform is a cloud-based solution designed for use directly by life sciences researchers who may not have software or bioinformatics expertise. It leverages proven open-source algorithms and applications developed at leading academic and research centers. After loading sequence data from any organism (human, animal, plant, or microbe), researchers are able to immediately perform analyses with reliable, scientifically vetted configurations, as cited in peer-reviewed journal publications. Visualization is provided through a variety of integrated graphical tools, including a private, secure version of the UCSC Genome Browser, the world's most widely used genome browser.

About Maverix Biomics

Based in San Mateo, CA and backed by leading venture capital firms and Silicon Valley investors, Maverix Biomics, Inc. provides researchers with a cloud-based platform to manage, analyze, and visualize genomic data, build Communities of Discovery, and place their data in context with the latest public data from the full spectrum of life, including human, plant, animal, or microbial organisms. For more information, visit www.maverixbio.com.

 

SOURCE Maverix Biomics



RELATED LINKS

http://www.maverixbio.com